Table 1.

Recent and ongoing clinical trials for treatment of pediatric ocular diseases according to ClinicalTrials.gov.

Identifier	Sponsor	Condition (s)	Intervention (s)
NCT01658839	Alcon Research	Pediatric glaucoma	Travoprost ophthalmic solution, 0.004% (new formulation)
NCT01652664	Alcon Research	Pediatric glaucoma Elevated IOP in pediatric patients Ocular hypertension in pediatric patients	Travoprost 0.004% PQ ophthalmic solution Timolol, 0.5% or 0.25% ophthalmic solution Travoprost vehicle
NCT00061516	Alcon Research	Glaucoma Ocular hypertension	BETAXON (levobetaxolol HCl) AZOPT (brinzolamide)
NCT00061542	Alcon Research	Glaucoma Ocular hypertension	BETOPTIC S (betaxolol HCl) Timolol gel-forming solution (timolol maleate)
NCT02102750	Santen Oy	Glaucoma Ocular hypertension	Preservative free tafluprost ophthalmic solution 0.0015% eye drops q.d., in both eyes for 7 to 9 days
NCT01959243	Bausch & Lomb Incorporated	Hyperemia	Brimonidine tartrate ophthalmic solution 0.025% (one drop of drug into each eye, four times daily for up to four weeks)
NCT01124045	Alcon Research	Cataracts Inflammation	Difluprednate ophthalmic emulsion, 0.05%; Prednisolone acetate ophthalmic suspension, 1.0%
NCT01527682	Azienda Ospedaliera Spedali Civili di Brescia	Childhood glaucoma	Latanoprost (prostaglandin analogue) 0.005% ophthalmic solution given once a day at nighttime (9:00 PM) Dorzolamide (potent inhibitor of carbonic anhydrase II) 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost
NCT01954082	NICHD Neonatal Research Network	ROP	Myo-inositol 5% injection
NCT02390531	Jaeb Center for Health Research (Collaborator: National Eye Institute)	ROP	Bevacizumab
NCT02164604	Kantonsspital Aarau (Collaborator: University Hospital Inselspital, Berne)	ROP	Intravitreal injection of 0.03 mL ranibizumab
NCT02504944	Azienda Ospedaliero, Universitaria Meyer	ROP	Propranolol 0.2% eye drops
NCT02134457	University Hospital Freiburg	ROP	Intravitreal anti-VEGF treatment with ranibizumab 0.12 mg or 0.20 mg
NCT01660620	Smith-Kettlewell Eye Research Institute (Collaborators: Ohio State University, University of Minnesota - Clinical and Translational Science Institute, University of Oklahoma, The University of Texas Health Science Center, Houston)	ROP	Betaxolol 0.25% (2 per day for 3 weeks)